458870.KQ
Seers
KOE · Healthcare · Medical - Specialties · KR
KRW 20,700.00
−0.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 97.0B | 48.2B | 8.1B | 1.9B | 1.2B |
| Cost of Revenue | 30.3B | 14.0B | 4.7B | 2.7B | 1.7B |
| Gross Profit | 66.7B | 34.2B | 3.4B | (824.5M) | (551.0M) |
| Operating Expenses | |||||
| R&D Expense | 6.1B | 4.6B | 4.1B | 3.5B | 2.8B |
| SG&A Expense | 9.9B | 5.6B | 4.0B | 2.4B | 4.2B |
| General & Admin Expense | 1.6B | 1.7B | 807.7M | 598.0M | 343.3M |
| Selling & Marketing Expense | 3.2B | 3.9B | 3.2B | 1.8B | 1.6B |
| Other Expenses | 11.3B | 7.8B | 3.9B | 3.1B | 415.5M |
| Total Operating Expenses | 24.6B | 17.9B | 12.1B | 9.0B | 7.4B |
| Cost and Expenses | 54.9B | 31.8B | 16.8B | 11.7B | 9.1B |
| Operating Income (EBIT) | 42.1B | 16.3B | (8.7B) | (9.8B) | (8.0B) |
| Non-Operating | |||||
| Interest Income | 271.1M | 235.6M | 278.6M | 89.1M | 54.3M |
| Interest Expense | 261.2M | 238.0M | 391.3M | 210.5M | 93.3M |
| Net Interest Income | 9.9M | (2.4M) | (112.7M) | (121.4M) | (39.0M) |
| Other Non-Op Income/Expense | (174.3M) | (154.1M) | (96.8M) | (113.5M) | 2.0M |
| Non-Operating Income (excl Interest) | 170.9M | (14.9M) | (294.5M) | (96.9M) | (95.3M) |
| EBT (Pre-Tax Income) | 41.9B | 16.2B | (8.8B) | (9.9B) | (8.0B) |
| Income Tax Expense | (10.8M) | 58.5M | 93.1M | — | — |
| Bottom Line | |||||
| Net Income | 42.0B | 16.1B | (8.9B) | (9.9B) | (8.0B) |
| Earnings from Cont. Ops | 41.9B | 16.0B | (8.9B) | (9.9B) | (8.0B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 42.0B | 16.1B | (8.9B) | (9.9B) | (8.0B) |
| Per Share | |||||
| Basic EPS | ₩1,104 | ₩426 | (₩251) | (₩302) | (₩247) |
| Diluted EPS | ₩1,094 | ₩426 | (₩251) | (₩302) | (₩247) |
| Revenue Per Share | ₩2,550 | ₩1,268 | ₩229 | ₩57 | ₩36 |
| Shares | |||||
| Basic Shares Outstanding | 38.1M | 38.0M | 35.4M | 32.9M | 32.3M |
| Diluted Shares Outstanding | 39.2M | 38.0M | 35.4M | 32.9M | 32.3M |
| Profitability Metrics | |||||
| EBITDA | 43.7B | 17.6B | (7.3B) | (8.7B) | (7.4B) |
| D&A | 1.6B | 1.3B | 1.1B | 989.0M | 510.9M |
| EBIT | 42.2B | 16.3B | (8.4B) | (9.7B) | (7.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026